Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Malaria Vaccines
Findings from New York University, University Cancer Institute provide new insights into malaria vaccines
February 24th, 2009
New investigation results, 'Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod,' are detailed in a study published in Infection and Immunity. According to recent research published in the journal Infection and Immunity, "Plasmodium sporozoites injected into the skin by malaria-infected mosquitoes can be effectively targeted by antibodies that block parasite invasion of host hepatocytes and thus prevent the subsequent development of blood stage infections responsible for clinical disease. Malaria subunit vaccines require potent adjuvants, as they lack known...
Source: Cancer Weekly (2009-02-24)
|
